Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test
Abstract
There is an ongoing debate as to whether SARS-CoV-2 antibodies can be found in patientswho have recovered from COVID-19 disease. Currently, there is no consensus on whether the antibodies, if present, are protective.
Our regular measurements of SARS-CoV-2 antibodies, starting in July 2020, have provided us with the opportunity of becoming acquainted with the five different immunoassays. A total of 149 patients were enrolled in our study.
We measured the samples using each immunoassay, then performing a virus neutralization test and comparing the results of SARS-CoV-2 antibodies with this test. We observed that the production of neutralizing antibodies is age-dependent.
Elderly patients have a higher proportion of high neutralizing titers than young patients. Based on our results, and in combination with the literature findings, we can conclude that the serological SARS-CoV-2 antibody measurement is a helpful tool in the fight against COVID-19.The assays can provide information about the patient's previous contact with the virus.
Anti-spike protein assays correlate well with the virus neutralization test and can be used in the screening of potential convalescent plasma donors.
